Back to top
more

Amgen (AMGN)

(Real Time Quote from BATS)

$285.22 USD

285.22
1,069,622

+0.55 (0.19%)

Updated Aug 7, 2025 01:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Sweta Killa headshot

Bet on Favorite Sector ETFs & Stocks This Earnings Season

Like the first three quarters of 2019, the earnings picture looks weak for Q4 thanks to tough comparisons and moderating economic growth.

Zacks Equity Research

Merck's Keytruda Gets FDA Nod for High-Risk Bladder Cancer

Merck's (MRK) Keytruda gets FDA's approval to treat certain patients with high-risk, non-muscle invasive bladder cancer.

Zacks Equity Research

Apellis' (APLS) PNH Drug Betters Alexion's Soliris in Study

Apellis Pharmaceuticals' (APLS) experimental drug pegcetacoplan outperformed Alexion's blockbuster medicine, Soliris, in a phase III head-to-head study. Shares soar.

Zacks Equity Research

Merck's Keytruda Misses One of Two Goals in Lung Cancer Study

Merck's (MRK) phase III first-line SCLC study fails to meet one of the two primary endpoints. It signs an oncology collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals.

Zacks Equity Research

Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Amgen Stock Up in a Year on Pipeline & Biosimilar Progress

Pipeline development and rapid progress in biosimilars program drive Amgen's (AMGN) stock 24% higher in the past year.

Zacks Equity Research

4 Reasons Why Investors Should Buy Alexion (ALXN) in 2020

Alexion's (ALXN) growth prospects look strong for 2020 as Soliris maintains momentum and Ultomiris gains further traction.

Zacks Equity Research

Amgen (AMGN) Upgraded to Buy: Here's What You Should Know

Amgen (AMGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

3 Investing Facts About Required Minimum Distributions You Need to Know - December 20, 2019

Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals

The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals

Zacks Equity Research

AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU

AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives approval in Europe for treating rheumatoid arthritis under the trade name of Rinvoq.

Zacks Equity Research

Amgen (AMGN) Dips More Than Broader Markets: What You Should Know

Amgen (AMGN) closed at $241.94 in the latest trading session, marking a -0.37% move from the prior day.

Zacks Equity Research

Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More

The biotech sector was in focus this week with pipeline and regulatory updates from quite a few players.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Apple, Cisco Systems, Oracle, HSBC and Amgen

The Zacks Analyst Blog Highlights: Apple, Cisco Systems, Oracle, HSBC and Amgen

Mark Vickery headshot

Top Analyst Reports for Apple, Cisco & Oracle

Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Cisco Systems (CSCO) and Oracle (ORCL).

Zacks Equity Research

Amarin Gains on FDA Approval of Vascepa Label Expansion

Amarin (AMRN) gains as FDA approves a label expansion of Vascepa to reduce cardiovascular risk.

Zacks Equity Research

Amgen's Osteoporosis Drug Evenity Gets Approval in Europe

The EC grants marketing authorization to Amgen (AMGN) and partner UCB's Evenity for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.

    Zacks Equity Research

    Amgen (AMGN) Gains But Lags Market: What You Should Know

    Amgen (AMGN) closed at $234.01 in the latest trading session, marking a +0.07% move from the prior day.

    Zacks Equity Research

    Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar

    The biotech sector witnesses pipeline updates from the annual ASH meet.

    Sweta Killa headshot

    Biotech ETFs Hit New Highs on Deal Activities

    Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

    Zacks Equity Research

    Healthpeak Amends & Extends Lease With Amgen in San Francisco

    Healthpeak's (PEAK) lease amendment and extension with Amgen at the Britannia Oyster Point of the former offers flexibility in addressing lease-expiration issue at this property.

    Zacks Equity Research

    Amgen Gets FDA Approval for J&J/Merck's Remicade Biosimilar

    FDA gives nod to Amgen's (AMGN) Avsola (ABP 710), a biosimilar of J&J's blockbuster rheumatoid arthritis drug, Remicade.

    Zacks Equity Research

    Biogen Up on New Data on Alzheimer's Candidate Aducanumab

    Biogen (BIIB) divulges new positive data on Alzheimer's candidate, aducanumab at CTAD. Stock rises.

    Zacks Equity Research

    Biogen's Shares Down on Rating Downgrade by Baird Analyst

    Biogen's (BIIB) shares decline following a rating downgrade by an analyst at Robert W. Baird on concerns related to approval of Alzheimer's disease candidate, aducanumab.

    Zacks Equity Research

    Merck's Keytruda Gets FDA's Priority Tag in Bladder Cancer

    Merck's (MRK) sBLA for Keytruda gets FDA's priority review status to treat certain patients with high-risk, non-muscle invasive bladder cancer.